<DOC>
	<DOCNO>NCT00293345</DOCNO>
	<brief_summary>This phase I trial study best dose 3-AP side effect give 3-AP together gemcitabine treat patient advance solid tumor lymphoma . Drugs use chemotherapy , 3-AP gemcitabine ( GEM ) , work different way stop growth cancer cell , either kill cell stop divide . 3-AP may help gemcitabine kill cancer cell make cell sensitive drug . 3-AP may also stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>3-AP Gemcitabine Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximal tolerable dose ( MTD ) 3-AP administer 24 hour infusion combination fixed-dose gemcitabine hydrochloride ( GEM ) patient advance solid tumor lymphomas . SECONDARY OBJECTIVES : I . To define qualitative quantitative toxicity 3-AP/GEM combination regard organ specificity , time course , predictability , reversibility . II . To document therapeutic response combination patient possible . III . To measure deoxycytidine triphosphate ( dCTP ) level peripheral blood mononuclear cell ( PBMCs ) treatment specify time try correlate finding activity toxicity 3-AP . IV . To perform limited pharmacokinetic analysis . OUTLINE : This dose-escalation study 3-AP ( Triapine® ) .Patients receive 3-AP ( Triapine® ) IV 24 hour follow gemcitabine hydrochloride IV 100-125 minute day 1 8 . Treatment repeat every 3 week 12 course absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 1 additional course therapy beyond documented CR.Cohorts 3-6 patient receive escalate dos 3-AP ( Triapine® ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity.After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically cytologically confirm advanced solid tumor lymphoma Disease consider incurable use standard treatment ECOG performance status ≤ 2 Life expectancy &gt; 12 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior study treatment No history allergic reaction attribute compound similar chemical biologic composition 3AP ( Triapine® ) and/or gemcitabine hydrochloride No known glucose6phosphate dehydrogenase ( G6PD ) deficiency No uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement No pulmonary disease ( e.g. , dyspnea rest , supplemental oxygen requirement , baseline oxygen saturation &lt; 92 % ) Prior gemcitabine hydrochloride allow give standard 30minute infusion At least 4 week since prior gemcitabine hydrochloride Patient may receive &lt; 2 line chemotherapy metastatic setting No prior 3AP ( Triapine® ) fixeddose gemcitabine hydrochloride At least 6 week since prior nitrosoureas mitomycin C More 3 week since prior radiotherapy No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>